Masimo (NASDAQ:MASI) Hits New 52-Week High – Here’s What Happened

Masimo Co. (NASDAQ:MASI)’s stock price reached a new 52-week high on Wednesday . The company traded as high as $184.51 and last traded at $179.93, with a volume of 107652 shares changing hands. The stock had previously closed at $180.36.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on MASI. Wells Fargo & Company increased their target price on Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a report on Wednesday, January 22nd. Stifel Nicolaus restated a “buy” rating and issued a $190.00 target price (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Piper Sandler increased their price target on shares of Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. Finally, Raymond James lifted their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $191.40.

Masimo Trading Down 4.1 %

The company has a market capitalization of $9.10 billion, a price-to-earnings ratio of 117.21 and a beta of 1.02. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The business’s 50 day moving average price is $172.90 and its two-hundred day moving average price is $151.29.

Institutional Trading of Masimo

Hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its stake in shares of Masimo by 19.8% in the 4th quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider’s stock valued at $1,338,509,000 after acquiring an additional 1,340,836 shares during the last quarter. Vanguard Group Inc. raised its position in Masimo by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider’s stock valued at $758,182,000 after purchasing an additional 66,215 shares during the last quarter. Capital Research Global Investors boosted its stake in shares of Masimo by 80.5% during the fourth quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider’s stock valued at $405,807,000 after purchasing an additional 1,094,647 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Masimo by 119.0% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider’s stock worth $286,823,000 after purchasing an additional 943,001 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. grew its holdings in shares of Masimo by 8.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,662,376 shares of the medical equipment provider’s stock worth $274,791,000 after purchasing an additional 135,888 shares during the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.